| Company | Clinical Program Title (Phase) | Disease |
|---|---|---|
| Advanced Cell Technology (ACTC) | Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells for Juvenile Macular Degeneration (Phase I/II) | Juvenile Macular Degeneration |
| Neuralstem, Inc (CUR) | NSI-189 for Major Depression (Phase Ia) | Major Depression |
| Athersys (ATHX) | MultiStem for Ulcerative Colitis (Phase II) | Ulcerative Colitis |
| Clinical Data (CLDA) | Stedivaze for Cardiac Stress Testing (Phase III) | Cardiac Stress Testing |
| Aastrom (ASTM) | Vascular Repair Cells for Peripheral Vascular Disease-related Critical Limb Ischemia (Phase IIb) | Critical Limb Ischemia |
| Xenoport (XNPT) | Horizant for Restless Leg Syndrome (NDA) | Restless Leg Syndrome |
| Delcath (DCTH) | Chemosaturation Therapy for Metastatic Melanoma in the Liver with Melphalan (NDA) | Metastatic Melanoma in Liver |
| Amarin (AMRN) | AMR101 for High Triglycerides and on Statin Therapy (mixed dyslipidemia) (Phase III) | High Triglycerides |
| Advanced Cell Technology (ACTC) | Myoblast Stem Cell Therapy for Heart Failure (Phase I) | Heart Failure |
| Amarin (AMRN) | AMR101 for Very High Triglycerides (Phase III) | Very High Triglycerides |